

# Financial Tear Sheet

## Corporate Profile

We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our collaborators – a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine, and pain.

## Stock Performance

### XENE (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$5.15</b>
<b>Change (%)</b>	▲ 0.10 (1.98%)
<b>Volume</b>	50,969
<b>52 Week Low</b>	\$2.10
<b>Market Cap</b>	\$90,912,620
<b>Rolling EPS</b>	-1.71
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	18,002,499



Data as of 04/23/18 12:56 p.m. ET

## Recent Press Releases & Upcoming Events

**March 28, 2018** - Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.

**March 13, 2018** - Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer

**March 7, 2018** - Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
04/18/18	CT ORDER
03/29/18	4
03/29/18	SC 13G/A
03/28/18	8-K

## Corporate Governance

Simon Pimstone, MBChB, Ph.D., FRCPC

Ian Mortimer, MBA, CPA, CMA

Ernesto Aycardi, M.D.

Robin Sherrington, Ph.D.

James Empfield, Ph.D.

Y. Paul Goldberg, MBChB, Ph.D., FRCPC

Charles Cohen, PhD

Jodi Regts, BA, MBA

Data provided by Nasdaq. Minimum 15 minutes delayed. View [Attributions and Sources](#)